NeuroPace, Inc. NPCE
12.31 USD -0.03 (-0.24%)
At closeNov 3, 2026, 4:01 PM EST
12.31 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
12.00 Day range 12.64
9.23 52-week range 19.60
- YTD
- -20.27%
- 1 year
- +30.96%
News
defenseworld.net CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast NeuroPace (NASDAQ: NPCE - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
benzinga.com This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.
benzinga.com Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18 Keybanc analyst Brett Fishbin initiates coverage on NeuroPace (NASDAQ:NPCE) with a Overweight rating and announces Price Target of $18.
defenseworld.net Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE Bank of America Corp DE reduced its stake in shares of NeuroPace, Inc. (NASDAQ: NPCE) by 85.5% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned…
zacks.com Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
zacks.com Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
defenseworld.net 2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. BlackRock Inc. bought a new stake in NeuroPace, Inc. (NASDAQ: NPCE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).…
businesswire.com NeuroPace to Participate in 2026 Cantor Global Healthcare Conference MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management…
businesswire.com NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management…
zacks.com NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
zacks.com Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
zacks.com NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
seekingalpha.com NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
zacks.com NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
marketbeat.com NeuroPace Q2 Earnings Call Highlights NeuroPace NASDAQ: NPCE reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook.…
zacks.com NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.- benzinga.com NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500 million-$101.500 million vs $99.913 million estimate.
benzinga.com NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 30.77 percent increase over losses of $(0.26) per…
businesswire.com NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday's pre-market session. The company's market cap stands at $1.4 million. OneMedNet (NASDAQ:ONMD) shares…
benzinga.com Avis Budget Posts Weak Q2 Results, Joins Fiverr International, Costar Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures mixed, Dow up 0.1%. Avis Budget Group (CAR) shares down 13.3% after missing earnings & sales estimates. Other stocks also down.
benzinga.com HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target HC Wainwright & Co. analyst Yi Chen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintains $20 price target.
seekingalpha.com NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript
marketbeat.com NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data NeuroPace NASDAQ: NPCE said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC)…
benzinga.com NeuroPace Asked To Submit Submission Issue Request By FDA For Its RNS System To Include Patients With Antiseizure Medication-Resistant Idiopathic Generalized Epilepsy; FDA Indicated PMA Supplment Not Approvable In Current Form NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of…
businesswire.com NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S.…- benzinga.com Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22 Mizuho analyst Anthony Petrone initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Price Target of $22.
zacks.com Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
zacks.com Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
benzinga.com NeuroPace To Highlight Expanding Role Of Responsive Neuromodulation In Epilepsy Care In 2026 ASSFN Meeting --ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations----NeuroPace to engage neurosurgeon…- benzinga.com HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20 HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $19 to $20.
benzinga.com NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript - benzinga.com NeuroPace Raises FY2026 Sales Guidance from $98.000M-$100.000M to $99.000M-$101.000M vs $98.910M Est NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $98.000 million-$100.000 million to $99.000 million-$101.000 million vs $98.910 million estimate.
- benzinga.com NeuroPace Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $22.068M Beat $21.644M Estimate NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.23) by 13.04 percent. This is a 4.76 percent increase over losses of $(0.21)…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Earnings Summary: NeuroPace Q4 
benzinga.com NeuroPace Q4 EPS $(0.08) Beats $(0.17) Estimate, Sales $26.588M Beat $24.791M Estimate NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.17) by 52.66 percent. This is a 55.56 percent increase over losses of $(0.18)…- benzinga.com Earnings Scheduled For March 3, 2026
benzinga.com Earnings Outlook For NeuroPace 
benzinga.com Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock - benzinga.com HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $19 HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $18 to $19.
- benzinga.com NeuroPace Submits Premarket Approval Supplement Application To FDA For Expansion Of Labeled Indication For RNS System NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S)…
- benzinga.com UBS Maintains Buy on NeuroPace, Raises Price Target to $22 UBS analyst Priya Sachdeva maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $18 to $22.
benzinga.com JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $20 JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $18 to $20.- benzinga.com NeuroPace Presents Preliminary 18-Month Safety And Effectiveness Results From Ongoing NAUTILUS1 Trial Evaluating RNS System As Adjunctive Therapy For Treatment Of ASM Resistant IGE With GTC Seizures, At AES Meeting -- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) ---- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC)…
- benzinga.com JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $18 JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $16 to $18.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday